Few papers have looked into the activity status of this pathway in PSCC, one of which was Ferrandiz-Pulido et al. [10] whom in 67 PSCC cases found p-mTOR (activated mTOR) and p-elF4E (a downstream effector protein of mTOR) immunoexpression was significantly increased in PSCC compared to adjacent normal tissues and associated with lymph node metastasis (p = 0.05 and p = 0.006, respectively). Here, MTOR is linked to metastatic malignant neoplasm in the lymph nodes.